Positive Long-Term Outlook for Crispr Therapeutics as Gene Editing Portfolio Makes Progress

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well-suited for targeting rare diseases or other disorders that are caused by genetic mutations.